Jianping Li

State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences & Peking Union Medical College
Tianjin, 300020, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Very-low-dose decitabine and rhTPO for thrombocytopenia in lower-risk myelodysplastic syndrome.

Very-low-dose decitabine and rhTPO for thrombocytopenia in lower-risk myelodysplastic syndrome.

Journal: Annals of hematology

Published: February 14, 2026

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.

Journal: The New England journal of medicine

Published: January 14, 2026

Low-dose cyclophosphamide combined with standard immunosuppressive therapy improves early response rates in severe aplastic anemia.

Low-dose cyclophosphamide combined with standard immunosuppressive therapy improves early response rates in severe aplastic anemia.

Journal: Frontiers in immunology

Published: November 06, 2025

Cyclosporine related adverse events in aplastic anemia patients treated with immunosuppressive therapy.

Cyclosporine related adverse events in aplastic anemia patients treated with immunosuppressive therapy.

Journal: Annals of hematology

Published: September 03, 2025

BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy.

BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy.

Journal: The New England journal of medicine

Published: June 11, 2025

Luspatercept for the treatment of lower-risk myelodysplastic syndrome with SF3B1 mutation: a real-world single-center research in China.

Luspatercept for the treatment of lower-risk myelodysplastic syndrome with SF3B1 mutation: a real-world single-center research in China.

Journal: Hematology (Amsterdam, Netherlands)

Published: June 06, 2025

Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial.

Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial.

Journal: American journal of hematology

Published: May 24, 2025

Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia.

Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia.

Journal: Blood

Published: February 27, 2025

The efficacy of immunosuppressive therapy with or without thrombopoietin receptor agonist in elderly patients with severe aplastic anemia.

The efficacy of immunosuppressive therapy with or without thrombopoietin receptor agonist in elderly patients with severe aplastic anemia.

Journal: Annals of hematology

Published: December 29, 2024

Efficacy and safety of avatrombopag in combination with standard immunosuppressive therapy for severe aplastic anemia.

Efficacy and safety of avatrombopag in combination with standard immunosuppressive therapy for severe aplastic anemia.

Journal: Experimental hematology

Published: August 21, 2024

Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemia.

Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemia.

Journal: Frontiers in immunology

Published: April 29, 2024

Development and validation of early death risk score model for emergency status prediction in very severe aplastic anemia.

Development and validation of early death risk score model for emergency status prediction in very severe aplastic anemia.

Journal: Frontiers in immunology

Published: February 27, 2023

Showing 1-12 of 42

Last Updated: 09/26/2026